PARN
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Paradigm Biopharmaceuticals Limited.
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
16
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Paradigm Biopharmaceuticals Limited. - Ordinary Fully Paid Deferred
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in PARN
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in PARN
N/A
PARN investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in PARN also invest in...
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is engaged in discovering, developing, and delivering pharmaceutical therapies. The company is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA) and mucopolysaccharidosis (MPS). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). The company develops PPS under the brand name Zilosul. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with MPS; treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).
π Performance (5Yr p.a)
-16.49%
π Share price
$0.60 AUD
𧬠BIOTECHNOLOGY
ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).
π Performance (5Yr p.a)
11.44%
π Share price
$88.35 AUD
π GLOBAL
ποΈ CONSUMER
π HIGH PRICE GROWTH
π INDUSTRIALS
Qantas Airways Ltd. engages in international and domestic air transportation services. The company is headquartered in Mascot, New South Wales. The principal activities of the Company include the operation of international and domestic air transportation services and provision of freight services and the operation of a frequent flyer loyalty program. The Companyβs segments include Qantas Domestic, Qantas International, Jetstar Group, Qantas Loyalty, and Corporate. Qantas Domestic is a carrier in the Australian domestic market measured by capacity. Qantas Domestic offers on-board Wi-Fi and upgrades to the domestic lounges. Qantas International is a carrier into and out of Australia, also targeting business and premium leisure customers who value the full-service experience. Jetstar Group has domestic and international routes in Australia, joint ventures in Singapore and Japan. Qantas Loyalty is comprised of consumer and SME coalition loyalty programs. Its airline brands operate regional, domestic, and international services.
π Performance (5Yr p.a)
10.10%
π Share price
$9.06 AUD
π HIGH PRICE GROWTH
βοΈ AIRLINES
VEU.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard All-World ex-US Shares Index ETF seeks to track the return of the FTSE All-World ex US Index before taking into account fees, expenses and tax
π Performance (5Yr p.a)
4.63%
π Share price
$96.67 AUD
β³οΈ DIVERSIFIED
π GLOBAL
Want more shares? Try these...